Pluripotent Stem Cells Derived Astrocytes and Insulin Secreting Cells for The Treatment of ALS Disease and Diabetes Respectively: Preclinical and Clinical Results

Time: 9:30 am
day: Day One


  • Intrathecal injection of human astrocytes (AstroRx) derived from allogeneic pluripotent stem cells are safe and demonstrate a clinically meaningful decline in disease progression
  • Sharing the preclinical work carried out to reach clinical stage, including CMC preclinical efficacy and safety studies
  • Preclinical development of insulin-dependent treatment for diabetes by generation of insulin secreting cells